EAU 2014

eau29th Annual European Association
of Urology (EAU) Congress
April 11 - 15, 2014

Stockholm, Sweden

#AUA14 - Early experience of radium-223 treatment for metastatic castrate resistant prostate cancer: A preliminary report - Session Highlights

ORLANDO, FL USA (UroToday.com) - Radium-223 has recently been introduced for the treatment of metastatic castrate resistant prostate cancer (mCRPC).

#AUA14 - Analysis of renal mass biopsy prior to extirpative surgery and validation of the Michigan Risk Stratification algorithm - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Hak Lee reviewed data of 47 patients undergoing renal mass biopsy (RMB) prior to curative intent surgery for small cortical renal masses. 96% of patients had CT-guided biopsy, and the average mass was 3.5 cm in diameter.

#AUA14 - Pilot evaluation of boiling histotripsy of the kidney: Assessment in human ex vivo kidneys and validation of the porcine model - Session Highlights

ORLANDO, FL USA (UroToday.com) - Histotripsy is a non-thermal pulsed high-intensity focused ultrasound technology that homogenizes a target tissue.

#AUA14 - Does fellow and chief-resident training affect perioperative outcomes of robot-assisted radical prostatectomy? - Session Highlights

ORLANDO, FL USA (UroToday.com) - Medical education has long had to strike a balance when providing adequate training to novices and young doctors.

#AUA14 - Crossfire: Controversies in Urology - Robots have made a difference in the outcomes for prostate cancer patients - Session Highlights

ORLANDO, FL USA (UroToday.com) - This reboot of the debate on robotic versus open radical prostatectomy (RP), proclaimed the “pterodactyls” (open debaters) versus the “hucksters” (robotics debaters) by moderator Dr. Joseph Smith, featured a face-off between Drs. Ashutosh Tewari and Mani Menon on the pro-side, for the robot, versus Drs. Joel Nelson and Herbert Lepor on the con-side.

EAU 2014 - Poster: A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC)

STOCKHOLM, SWEDEN (UroToday.com) - Presented by D Petrylak,1 D Smith,2 L Appleman,3 M Fleming,4 A Hussain,5 R Dreicer,6 AO Sartor,7 N Shore,8 NJ Vogelzang,9 H Youssoufian,10 VA DiPippo,10 N Stambler,10 K Huang,10 RJ Israel10 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

STOCKHOLM, SWEDEN (UroToday.com) - Presented by T. Tammela,1 C. Massard,2 P. Bono,3 P. Langmuir,4 J. Aspegren,5 A. Vuorela,5 M.V.J. Mustonen,5 and K. Fizazi2 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Greater short-term relief of lower urinary tract symptoms in prostate cancer patients treated with degarelix compared to goserelin plus bicalutamide: Results of a pooled analysis

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Malcolm Mason,1 Pierre Richaud,2 Zsolt Bosnyak,3 Anders Malmberg,3 Anders Neijber3 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Consistent long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: Final results of repeated treatments up to 4 years

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Gilles Karsenty,1 Heinrich Schulte-Baukloh,2 Roger Dmochowski,3 Karen Ethans,4 Brenda Jenkins,5 Steven Guard,6 Ho-Jin Lee,7 Michael Kennelly8 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: OnabotulinumtoxinA reduces urinary incontinence and improves quality of life in overactive bladder patients regardless of use of clean intermittent catheterisation or the presence of urinary tract infection

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Karel Everaert,1 Jennifer Gruenenfelder,2 Heinrich Schulte-Baukloh,3 Steven Guard,4 Yan Zheng,5 David Sussman6 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: An economic model to investigate differences in resource utilisation associated with the use of BOTOX® to manage urinary incontinence in patients with idiopathic overactive bladder in the United Kingdom

STOCKHOLM, SWEDEN (UroToday.com) - Presented by C. Loveman,1 J. Millen,1 R. Zeidman,2 and L. Ruff1 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Consistent improvements in urinary urgency following repeat onabotulinumtoxinA treatments in patients with overactive bladder syndrome and urinary incontinence

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Karl-Dietrich Sievert,1 Christopher Chapple,2 David Sussman,3 Sidney Radomski,4 Peter Sand,5 Steven Guard,6 Christopher Nardo,7 Jihao Zhou,8 Victor Nitti9 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Cost-utility analysis of onabotulinumtoxinA vs best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Nick Freemantle,1 Kristin Khalaf,2 Daisy Ng-Mak,2,* Clara Loveman,3 Sanja Stanisic,4 Dmitry Gultyaev,5 Johanna Lister,5 and Marcus Drake6 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial

STOCKHOLM, SWEDEN (UroToday.com) - Presented by L. Klotz, C. O’Callaghan, D. Dearnaley, T. Higano, A. Horwitz, S. Malone , Y. Liu, L. Goldenberg, M. Gospodarowicz, and J. Crook at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase and prostate-specific antigen in patients with castration-resistant prostate cancer and symptomatic bone metastases from the phase 3 ALSYMPCA trial

STOCKHOLM, SWEDEN (UroToday.com) - Presented by D. Heinrich,1 C. Parker,2 M. Shan,3 S. Wilhelm,3 M. Wahba,3 J. Garcia-Vargas,3 C.G. O’Bryan-Tear,4 O. Sartor5 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Emmanuel S. Antonarakis,1 Adam S. Kibel,2 George Adams,3 Lawrence I. Karsh,4 Aymen Elfiky,2 Neal D. Shore,5 Nicholas J. Vogelzang,6 John M. Corman,7 Robert C. Tyler,8 Candice McCoy,8 Todd DeVries,8 Nadeem Sheikh,8 and Charles G. Drake,1, 9 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Michael Stöckle,1 Thomas Flaig,2 Carsten H. Ohlmann,1 Howard I. Scher,3 Johann S. de Bono,4 Dana E. Rathkopf,3 Charles J. Ryan,5 Thian Kheoh,6 Jinhui Li,7 Mary B. Todd,8 Thomas W. Griffin,6 Arturo Molina,9 and Karim Fizazi10 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Poster: Impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Dirk L. Schrijvers,1 Thian Kheoh,2 Margaret K. Yu,2 Matthew R. Smith,3 Eric J. Small,4 Peter F.A. Mulders,5 Karim Fizazi,6 Dana E. Rathkopf,7 Fred Saad,8 Howard I. Scher,7 Stephane Oudard,9 Joaquim Bellmunt,10 Mary-Ellen Taplin,10 Ian D. Davis,11 Andrew Protheroe,12 Arturo Molina,13 Thomas W. Griffin,2 Johann S. de Bono,14 and Charles J. Ryan4 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU 2014 - Nephron sparing surgery does not decrease other-causes mortality relative to radical nephrectomy in patients with clinical T1a-T1b renal mass: Results from a large multi-institutional study - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - In patients with small renal masses, nephron-sparing surgery (NSS) may improve all-cause mortality when compared to radical nephrectomy (RN).

EAU 2014 - A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - The primary endpoint of this study was cellular immune response (ELISPOT to PA2024 [PAP-GMCSF]) with humoral and cytokine responses, product parameters, and safety being their secondary endpoints.

Page 1 of 4
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe